Developing live biotherapeutics that target the core drivers of disease
We use our deep understanding of the human microbiome, the interactions between microbes and the body, and anaerobic microbiology to create live biotherapeutic products (LBPs). These products aim to prevent diseases in both mothers and infants, including conditions like atopic diseases, women’s health issues, and rare pediatric diseases. Our focus is on diseases where the human microbiota (the collection of microbes in the body) plays a crucial role in disease prevention and immune system regulation, especially where there are few existing treatments available.
At the frontier of modern medicine
By targeting the microbiome, we aim to address not just the symptoms of diseases, but to promote overall health by considering the whole person.
Our patient-centric Precision Symbiotics Platform™ leverages a proprietary human microbiota biobank, in vitro and in vivo therapeutic phenotype screening, and anaerobic manufacturing expertise to rationally design mixed-strain live biotherapeutic products. Our end-to-end approach enables efficient development toward human proof-of-concept trials, integrating ecosystem approaches and precision medicine concepts to advance the future of medicine. Our Precision Symbiotics Platform™ has enabled us to advance multiple programs from discovery to preclinical and clinical development stages. Our multi-strain lead program, STMC-103H is currently in phase 2 clinical development
for the prevention of atopic diseases, including atopic dermatitis, food allergy, and asthma, in newborns. We have successfully manufactured and scaled STMC-103H, completed a First-In-Human safety clinical trial in children and adults, and received Fast Track Designation for this novel approach for the prevention of allergic diseases. Siolta was also awarded a $2.9M NIH grant to further optimize its large-scale proprietary live biotherapeutic manufacturing methods. We plan to initiate two new INDs in the next 18 months in the areas of women’s health and rare pediatric diseases.
Our Mission
To develop live biotherapeutics that target the core drivers of disease
Susan Lynch (the University of California at San Francisco, or UCSF) and Nikole Kimes (Siolta, formerly UCSF) co-founded Siolta Therapeutics in partnership with Samir Kaul (Khosla Ventures) in 2016. Our combined expertise in the formation of successful startup companies and the strong scientific background of our team have allowed Siolta to advance multiple novel live biotherapeutics products into preclinical and clinical-stage development.
Meet Our Team